Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17469459 | 0.86 | GBA1 (0.35) | GBA1 | |
| SCHEMBL19656077 | 0.79 | GBA1 (0.38) | GBA1 | |
| SCHEMBL24326441 | 0.79 | GBA1 (0.38) | GBA1PTPN1 | |
| SCHEMBL17857892 | 0.76 | LGALS8 (0.31) | — | |
| SCHEMBL17448163 | 0.76 | LGALS8 (0.31) | — | |
| SCHEMBL19934858 | 0.74 | GBA1 (0.39) | GBA1 | |
| SCHEMBL23191952 | 0.74 | GBA1 (0.39) | GBA1 | |
| SCHEMBL17179645 | 0.73 | GBA1 (0.38) | GBA1 | |
| SCHEMBL18517492 | 0.73 | GBA1 (0.38) | GBA1 | |
| SCHEMBL17452395 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170362605-A1 | TERMINAL MODIFICATIONS OF POLYNUCLEOTIDES | MODERNA THERAPEUTICS, INC. | 2017-12-21 | — | — | US | disclosed |
| US-20170210788-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF INTRABODIES | MODERNATX, INC. | 2017-07-27 | — | — | US | disclosed |
| US-20170202979-A1 | TERMINAL MODIFICATIONS OF POLYNUCLEOTIDES | MODERNATX, INC. | 2017-07-20 | — | — | US | disclosed |
| US-20170204422-A1 | CIRCULAR POLYNUCLEOTIDES | ARES CAPITAL CORPORATION, AS AGENT | 2017-07-20 | — | — | US | disclosed |
| US-20170204152-A1 | CHIMERIC POLYNUCLEOTIDES | MODERNA THERAPEUTICS, INC. (US) | 2017-07-20 | — | — | US | disclosed |
| WO-2016011226-A1 | CHIMERIC POLYNUCLEOTIDES | MODERNA THERAPEUTICS, INC. (US) | 2016-01-21 | — | — | WO | disclosed |
| WO-2016011222-A2 | CIRCULAR POLYNUCLEOTIDES | MODERNA THERAPEUTICS, INC. (US) | 2016-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170204152-A1 | CHIMERIC POLYNUCLEOTIDES | NSUN3, TRDMT1, NSUN2 | GBA1 2231/4885PTPN1 315/4885 |
| US-20170204422-A1 | CIRCULAR POLYNUCLEOTIDES | POLN, POLRMT, POLI | GBA1 1588/4885PTPN1 591/4885 |
| US-20170210788-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF INTRABODIES | PAICS, IGF2BP1, FCGRT | GBA1 633/4885PTPN1 2234/4885 |
| US-20170362605-A1 | TERMINAL MODIFICATIONS OF POLYNUCLEOTIDES | RNGTT, TRDMT1, RNMT | GBA1 2145/4885PTPN1 904/4885 |
| US-20170202979-A1 | TERMINAL MODIFICATIONS OF POLYNUCLEOTIDES | POLM, POLN, POLRMT | GBA1 1396/4885PTPN1 1436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.